Phase 2 N=127 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Cushing's Syndrome
Primary: Number of Participants With Adverse/Serious Adverse Events — 115; 50; 34; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Motivation Skills Training for Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Motivation and Pleasure Scale (MAP) — 0.50 score on a scale
N/A N=11 Effects of Gamma-tACS on Memory and Sleep
Transcranial Alternating Current Stimulation · Aging · Cognitive Decline
Primary: Percent of Participants Tolerating Cognitive Testing During tACS — 100; 100 percentage of participants
Phase 2 N=117 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma
Primary: Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by…
Phase 2 N=6 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Accelerated/Blast-phase Myeloproliferative Neoplasm · Chronic-phase Myelofibrosis · IDH2 Mutation
Primary: Number of MPN Participants With Response — 2 Participants
Phase 4 N=68 Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
Mitochondrial Diseases
Primary: Difference in Mitochondrial Respiratory Function — 36; 32; -3 pmols/s/mg — p=0.6051
Phase 3 N=195 Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
Prostatic Neoplasms · Prostate Cancer
Primary: Patient-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity — 86.8; 90.0; 86.9 % Sensitivity
Phase 2 N=200 Cold Stored Platelet in Hemorrhagic Shock
Trauma · Hemorrhage
Primary: Study Feasibility — 91; 82 Participants
N/A N=116 Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
Relapsing-Remitting Multiple Sclerosis
Primary: Annualized Relapse Rate in the Year Prior to Treatment Initiation With Cladribine Tablets — 0.595 Relapse per year
N/A N=150 Initial Graft Tension and ACL Surgery
Anterior Cruciate Ligament Rupture
Primary: Radiographic Joint Space Narrowing (Midpoint Method) — 0.0613; 0.0634; -0.0321; 0.1374 mm — p=.27
Phase 2 N=1,083 A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
Healthy Participants
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 49.4; 45.8; 54.7; 10.5 Percentage of participants
Phase 2 N=187 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
NSCLC · HNSCC
Primary: Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed) — 46; 3; 11 Participants
Phase 1 N=43 Boost Study 31380 (mHealth)
Addiction
Primary: Interaction Engagement, as Assessed by Interactions Completed — 7.3 interactions
Early Phase 1 N=188 Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery
Obstructive Sleep Apnea · Tonsillitis
Primary: Number of Patients Requiring Rescue Intravenous Opioid — 48; 66 Participants
Phase 3 N=71 Dupilumab in CRSsNP
Chronic Rhinosinusitis Without Nasal Polyps · Sinusitis · Chronic Sinusitis
Primary: Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group — -6.63 Score…